Spinal Cord Stimulator (SCS) Changes Patients’ Lives

Patients discuss their experiences with the spinal cord stimulator, as a breakthrough in treatment for common chronic pain conditions.

A spinal cord stimulator (SCS) is a minimally invasive surgery where electro-leads are threaded by needle into areas along a patient’s spine to allow stimulated vibrations to be sent throughout the nerves in the area to reduce pain. The SCS is controlled by a remote device to help eliminate pain through different programs unique to the patient.

When I came to pain management they told me about a pain stimulator. I tried it, and I got good results, so I went for the surgery and it is unbelievable. I am now weaning off of the meds and my pain is so much better…it’s immeasurable how much better I am. There are days when I don’t even have pain…which is unheard of,” states Phyllis, PA Pain and Spine Patient, on SCS experience.

Treatment with a SCS may help for those coping with a previously failed back surgery, neuropathy, sciatica, and more. This treatment is typically used when other conventional methods, such as medication or injections, have failed in treating the corresponding condition.

Prior to the full procedure taking place, eligible patients have the opportunity to participate in a SCS trial where a non-surgical procedure takes place to replicate the sensations provided by the SCS. This is a 45-60 minute procedure done in an out-patient, regular office setting and the trial runs for 3-5 days to determine if the full procedure may help reduce or eliminate the patient’s pain.

SCS is an effective way to help treat specific pain-related chronic conditions without the use of medications, and brings immense relief to thousands of patients around the U.S.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”